Oppenheimer analyst Rick Schafer raised his price target for Texas Instruments to $140 from $120 and maintained an Outperform rating ahead of the company's earnings report on January 22. In a research note to investors, Schafer says he sees Q4 EPS and sales in line with the Street's $1.02/$3.26B estimates and sees upside to his Q1 EPS/sales view of $1.02/$3.15B following five quarters of cuts as comps begin to ease.

Baird raised the firm's price target on Texas Instruments to $175 from $125 and keeps a Neutral rating on the shares. The firm said any unexpected/incremental softening in demand would likely trigger price cuts given the current environment of low lead times and excess capacity, and the shape of 2H recovery will be critical in addressing inventory levels.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

TD Cowen analyst Joshua Buchalter raised the firm's price target on Texas Instruments to $175 from $160 and keeps a Hold rating on the shares. The firm said the print wasn't great but an important improvement and positive indicator on stability for the group. That said, numbers still need to move meaningfully higher to build medium-term valuation support or material buyback growth.

BofA raised the firm's price target on Texas Instruments (TXN) to $190 from $175 and keeps a Neutral rating on the shares. TI's small Q1 beat and inline but sequentially rising Q2 sales guidance, "while modest, potentially marks a recovery inflection in industrial chip demand," with positive read-across for U.S. peers such as Analog Devices (ADI), Microchip (MCHP), NXP Semiconductors (NXPI) and On Semiconductor (ON), the analyst tells investors. However, despite an expected recovery, TI's sustained high capex intensity could keep reported calendar year 2024-26 pro-forma EPS below $6 per share, the analyst added.